Can a pill make CAR T-Cell therapy last longer?
NCT ID NCT07532525
First seen Jun 27, 2026 · Last updated Jul 17, 2026 · Updated 2 times
Summary
This early-phase trial tests whether the drug pomalidomide can improve the effects of CAR T-cell therapy in people with B-cell leukemias or lymphomas that have returned or not responded to treatment. The study will enroll 12 adults who have already received CAR T-cell therapy. Researchers want to see if pomalidomide is safe and whether it helps CAR T-cells stay active longer in the body.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- pomalidomide
- What this could lead to
- If it works, this could point toward a way to make CAR T-cell therapy more effective and longer-lasting for people with hard-to-treat B-cell cancers.
- What could go wrong
- This is a very early, small phase 1 trial with only 12 participants. It is primarily testing safety, not yet whether the combination actually works better. Pomalidomide can cause side effects like low blood counts and blood clots.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECURRENT B ACUTE LYMPHOBLASTIC LEUKEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
University of Michigan Rogel Cancer Center
RECRUITINGAnn Arbor, Michigan, 48109, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can engineered immune cells outsmart resistant blood cancers?
- Immunotherapy combo shows promise for Tough-to-Treat blood cancers
- Engineered immune cells take on tough blood cancers in early trial
- Brain training before CAR-T may protect memory, study hopes
- Triple-Target CAR T-Cells offer new hope for tough blood cancers
- Supercharged immune cells take on tough B-Cell cancers in early trial